PRMT2: Protein Arginine Methyltransferase 2
A type I arginine methyltransferase involved in transcriptional regulation, RNA processing, and signal transduction.
Gene Information Card
| Symbol | PRMT2 |
|---|---|
| Full Name | Protein arginine methyltransferase 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 21q22.3 |
| NCBI Gene ID | 3275 ncbi.nlm.nih.gov/gene/3275 |
| Ensembl ID | ENSG00000160209 |
| UniProt ID | P55345 |
| OMIM ID | 601961 |
| HGNC ID | 9376 |
| Aliases | HRMT1L1, IBP72, MGC111073 |
Description
PRMT2 (Protein Arginine Methyltransferase 2) encodes a type I arginine methyltransferase that catalyzes the formation of asymmetric dimethylarginine (ADMA) on histone and non-histone proteins. It functions as a transcriptional coactivator, interacting with nuclear receptors and other transcription factors, and is involved in RNA splicing, cell cycle regulation, and signal transduction. PRMT2 is widely expressed and has been implicated in cancer, particularly breast cancer, and inflammatory responses.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast Cancer | PRMT2 overexpression promotes cell proliferation and migration; acts as a coactivator of estrogen receptor alpha (ERα). | PMID: 21947297, COSMIC |
| Prostate Cancer | PRMT2 enhances androgen receptor (AR) transcriptional activity, contributing to tumor growth. | PMID: 21947297 |
| Inflammatory Diseases | PRMT2 regulates NF-κB signaling and cytokine expression, influencing inflammation. | PMID: 21947297 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Breast | 15.2 | Medium |
| Prostate | 12.8 | Medium |
| Testis | 18.5 | High |
| Brain | 8.3 | Low |
| Liver | 6.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 20.1 | ERα-positive cell line |
| LNCaP (prostate cancer) | 16.4 | Androgen-sensitive |
| HEK293 (embryonic kidney) | 12.5 | Common model |
| HeLa (cervical cancer) | 14.7 | High expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1132C>T (p.Arg378Trp) | Missense | <0.01% | Unknown functional effect |
| c.154G>A (p.Gly52Arg) | Missense | <0.01% | Potential loss of methyltransferase activity |
Mutation functional classification
Loss of Function (LOF)
Missense mutations in the catalytic domain (e.g., p.Gly52Arg) may reduce methyltransferase activity.
Gain of Function (GOF)
Not well characterized; overexpression in cancer suggests potential gain-of-function via increased coactivator activity.
Dominant Negative (DN)
No dominant-negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Arginine and proline metabolism
• Estrogen signaling pathway
• Androgen receptor signaling pathway
• NF-kappa B signaling pathway
Protein Summary
PRMT2 is a 433-amino acid protein containing a conserved methyltransferase domain and an SH3 domain. It catalyzes the transfer of methyl groups from S-adenosylmethionine to arginine residues, producing asymmetric dimethylarginine. PRMT2 interacts with nuclear receptors (e.g., ERα, AR) and transcription factors to modulate gene expression. It also participates in pre-mRNA splicing by methylating splicing factors. The protein is predominantly nuclear but can shuttle to the cytoplasm.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PRMT2 Knockout HEK293 Cell Line | EDJ-KQ4937 | Human | 3275 | Details Get a Quote |
| PRMT2 Knockout A-549 Cell Line | EDJ-KQ27779 | Human | 3275 | Details Get a Quote |
| PRMT2 Knockout HCT 116 Cell Line | EDJ-KQ27780 | Human | 3275 | Details Get a Quote |
| PRMT2 Knockout HeLa Cell Line | EDJ-KQ27781 | Human | 3275 | Details Get a Quote |
